Dopamine transporter mutants selectively enhance MPP+ transport

S. Kitayama, J. B. Wang, G. R. Uhl

Research output: Contribution to journalArticle

Abstract

MPP+ (1-methyl-4-phenylpyridinium), a dopaminergic neurotoxin that provides the best available experimental model of Parkinson's disease, is selectively concentrated in dopamine neurons by the dopamine transporter (DAT). DAT also serves as a primary recognition site for cocaine. To help define selective molecular mechanisms by which MPP+ uptake occurs, we have tested dopamine transporters mutated in several residues for their abilities to accumulate dopamine and MPP+, and to bind a cocaine analog. Mutants in DAT 7th and 11th hydrophobic putative transmembrane domains increase MPP+ uptake velocity and affinity (1/K(D)), respectively. These mutations exert much more modest effects on dopamine uptake and have little impact on cocaine analog binding. These findings provide the first example of mutations that enhance transport and identify specific DAT amino acids selectively involved in neurotoxin uptake. They may also have implications for the feasibility of developing drugs that could specifically block accumulation of Parkinsonism- inducing neurotoxins.

Original languageEnglish (US)
Pages (from-to)58-62
Number of pages5
JournalSynapse
Volume15
Issue number1
StatePublished - 1993

Fingerprint

Dopamine Plasma Membrane Transport Proteins
Neurotoxins
Cocaine
Parkinsonian Disorders
Dopamine
1-Methyl-4-phenylpyridinium
Mutation
Dopaminergic Neurons
Theoretical Models
Amino Acids
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Physiology
  • Neuroscience(all)
  • Pharmacology

Cite this

Kitayama, S., Wang, J. B., & Uhl, G. R. (1993). Dopamine transporter mutants selectively enhance MPP+ transport. Synapse, 15(1), 58-62.

Dopamine transporter mutants selectively enhance MPP+ transport. / Kitayama, S.; Wang, J. B.; Uhl, G. R.

In: Synapse, Vol. 15, No. 1, 1993, p. 58-62.

Research output: Contribution to journalArticle

Kitayama, S, Wang, JB & Uhl, GR 1993, 'Dopamine transporter mutants selectively enhance MPP+ transport', Synapse, vol. 15, no. 1, pp. 58-62.
Kitayama S, Wang JB, Uhl GR. Dopamine transporter mutants selectively enhance MPP+ transport. Synapse. 1993;15(1):58-62.
Kitayama, S. ; Wang, J. B. ; Uhl, G. R. / Dopamine transporter mutants selectively enhance MPP+ transport. In: Synapse. 1993 ; Vol. 15, No. 1. pp. 58-62.
@article{74de5a97404d417db105621c242e68b7,
title = "Dopamine transporter mutants selectively enhance MPP+ transport",
abstract = "MPP+ (1-methyl-4-phenylpyridinium), a dopaminergic neurotoxin that provides the best available experimental model of Parkinson's disease, is selectively concentrated in dopamine neurons by the dopamine transporter (DAT). DAT also serves as a primary recognition site for cocaine. To help define selective molecular mechanisms by which MPP+ uptake occurs, we have tested dopamine transporters mutated in several residues for their abilities to accumulate dopamine and MPP+, and to bind a cocaine analog. Mutants in DAT 7th and 11th hydrophobic putative transmembrane domains increase MPP+ uptake velocity and affinity (1/K(D)), respectively. These mutations exert much more modest effects on dopamine uptake and have little impact on cocaine analog binding. These findings provide the first example of mutations that enhance transport and identify specific DAT amino acids selectively involved in neurotoxin uptake. They may also have implications for the feasibility of developing drugs that could specifically block accumulation of Parkinsonism- inducing neurotoxins.",
author = "S. Kitayama and Wang, {J. B.} and Uhl, {G. R.}",
year = "1993",
language = "English (US)",
volume = "15",
pages = "58--62",
journal = "Synapse",
issn = "0887-4476",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Dopamine transporter mutants selectively enhance MPP+ transport

AU - Kitayama, S.

AU - Wang, J. B.

AU - Uhl, G. R.

PY - 1993

Y1 - 1993

N2 - MPP+ (1-methyl-4-phenylpyridinium), a dopaminergic neurotoxin that provides the best available experimental model of Parkinson's disease, is selectively concentrated in dopamine neurons by the dopamine transporter (DAT). DAT also serves as a primary recognition site for cocaine. To help define selective molecular mechanisms by which MPP+ uptake occurs, we have tested dopamine transporters mutated in several residues for their abilities to accumulate dopamine and MPP+, and to bind a cocaine analog. Mutants in DAT 7th and 11th hydrophobic putative transmembrane domains increase MPP+ uptake velocity and affinity (1/K(D)), respectively. These mutations exert much more modest effects on dopamine uptake and have little impact on cocaine analog binding. These findings provide the first example of mutations that enhance transport and identify specific DAT amino acids selectively involved in neurotoxin uptake. They may also have implications for the feasibility of developing drugs that could specifically block accumulation of Parkinsonism- inducing neurotoxins.

AB - MPP+ (1-methyl-4-phenylpyridinium), a dopaminergic neurotoxin that provides the best available experimental model of Parkinson's disease, is selectively concentrated in dopamine neurons by the dopamine transporter (DAT). DAT also serves as a primary recognition site for cocaine. To help define selective molecular mechanisms by which MPP+ uptake occurs, we have tested dopamine transporters mutated in several residues for their abilities to accumulate dopamine and MPP+, and to bind a cocaine analog. Mutants in DAT 7th and 11th hydrophobic putative transmembrane domains increase MPP+ uptake velocity and affinity (1/K(D)), respectively. These mutations exert much more modest effects on dopamine uptake and have little impact on cocaine analog binding. These findings provide the first example of mutations that enhance transport and identify specific DAT amino acids selectively involved in neurotoxin uptake. They may also have implications for the feasibility of developing drugs that could specifically block accumulation of Parkinsonism- inducing neurotoxins.

UR - http://www.scopus.com/inward/record.url?scp=0027318006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027318006&partnerID=8YFLogxK

M3 - Article

C2 - 8310426

AN - SCOPUS:0027318006

VL - 15

SP - 58

EP - 62

JO - Synapse

JF - Synapse

SN - 0887-4476

IS - 1

ER -